探讨重组人白介素-11治疗急性白血病化疗后血小板减少的临床疗效  

Discussion on the clinical efficacy of recombinant human interleukin-11 in the treatment of thrombocytopenia after chemotherapy for acute leukemia

作　　者：刘越 LIU Yue(Hematology Department,Dandong Central Hospital,Dandong 118000,China)

机构地区：[1]丹东市中心医院血液科,118000

出　　处：《中国实用医药》2021年第1期132-134,共3页China Practical Medicine

摘　　要：目的探讨重组人白介素-11治疗急性白血病化疗后血小板减少的临床疗效。方法80例急性白血病化疗后血小板减少患者为研究对象,依据治疗方法不同分为研究组与对照组,各40例。对照组静脉输注血小板,研究组注射重组人白介素-11。对比两组患者临床疗效。结果研究组总有效率为97.5%,高于对照组的75.0%,差异具有统计学意义(P<0.05)。结论实施重组人白介素-11治疗可以使急性白血病化疗后血小板减少患者血小板有效恢复,临床中重组人白介素-11在急性白血病化疗后血小板减少治疗中效果显著,值得在临床推广。Objective To discuss the clinical efficacy of recombinant human interleukin-11 in the treatment of thrombocytopenia after chemotherapy for acute leukemia.Methods A total of 80 patients with thrombocytopenia after chemotherapy for acute leukemia as study subjects were divided into research group and control group according to different treatment methods,with 40 cases in each group.The control group received intravenous infusion of platelets,and the research group received recombinant human interleukin-11.The clinical efficacy of the two groups was compared.Results The total effective rate of the research group was 97.5%,which was higher than 75.0%of the control group,and the difference was statistically significant(P<0.05).Conclusion Recombinant human interleukin-11 can effectively restore platelets of patients with thrombocytopenia after chemotherapy for acute leukemia.In clinic,recombinant human interleukin-11 has a significant effect in the treatment of acute leukemia chemotherapy-related thrombocytopenia and is worthy of clinical promotion.

关 键 词：白血病化疗 血小板减少 重组人白介素-11 

分 类 号：R733.71[医药卫生—肿瘤]